171 related articles for article (PubMed ID: 34896453)
1. Screening of potential spike glycoprotein / ACE2 dual antagonists against COVID-19 in silico molecular docking.
Yu R; Li P
J Virol Methods; 2022 Mar; 301():114424. PubMed ID: 34896453
[TBL] [Abstract][Full Text] [Related]
2. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
Shahbazi B; Mafakher L; Teimoori-Toolabi L
J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
[TBL] [Abstract][Full Text] [Related]
3. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
4. Spike protein recognizer receptor ACE2 targeted identification of potential natural antiviral drug candidates against SARS-CoV-2.
Pokhrel S; Bouback TA; Samad A; Nur SM; Alam R; Abdullah-Al-Mamun M; Nain Z; Imon RR; Talukder MEK; Tareq MMI; Hossen MS; Karpiński TM; Ahammad F; Qadri I; Rahman MS
Int J Biol Macromol; 2021 Nov; 191():1114-1125. PubMed ID: 34592225
[TBL] [Abstract][Full Text] [Related]
5. Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents.
Mei J; Zhou Y; Yang X; Zhang F; Liu X; Yu B
J Ethnopharmacol; 2021 Oct; 278():114303. PubMed ID: 34102269
[TBL] [Abstract][Full Text] [Related]
6. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
[TBL] [Abstract][Full Text] [Related]
7. A potential antiviral activity of Esculentoside A against binding interactions of SARS-COV-2 spike protein and angiotensin converting enzyme 2 (ACE2).
Zeng MS; Yu WD; Wang HX; Liu JY; Xu PP
Int J Biol Macromol; 2021 Jul; 183():2248-2261. PubMed ID: 34111482
[TBL] [Abstract][Full Text] [Related]
8. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
Xiang Y; Wang M; Chen H; Chen L
Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
[TBL] [Abstract][Full Text] [Related]
9. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
10. In silico drug repurposing for coronavirus (COVID-19): screening known HCV drugs against the SARS-CoV-2 spike protein bound to angiotensin-converting enzyme 2 (ACE2) (6M0J).
Kalamatianos KG
Mol Divers; 2023 Jun; 27(3):1087-1099. PubMed ID: 35739375
[TBL] [Abstract][Full Text] [Related]
11. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
Molecules; 2021 May; 26(11):. PubMed ID: 34072087
[TBL] [Abstract][Full Text] [Related]
12. Screening S protein - ACE2 blockers from natural products: Strategies and advances in the discovery of potential inhibitors of COVID-19.
Ma LL; Liu HM; Liu XM; Yuan XY; Xu C; Wang F; Lin JZ; Xu RC; Zhang DK
Eur J Med Chem; 2021 Dec; 226():113857. PubMed ID: 34628234
[TBL] [Abstract][Full Text] [Related]
13. Phytoconstituents from Moringa oleifera fruits target ACE2 and open spike glycoprotein to combat SARS-CoV-2: An integrative phytochemical and computational approach.
Siddiqui S; Ahmad R; Alaidarous M; Zia Q; Ahmad Mir S; Alshehri B; Srivastava A; Trivedi A
J Food Biochem; 2022 May; 46(5):e14062. PubMed ID: 35043973
[TBL] [Abstract][Full Text] [Related]
14. An angiotensin-converting enzyme-2-derived heptapeptide GK-7 for SARS-CoV-2 spike blockade.
Han S; Zhao G; Wei Z; Chen Y; Zhao J; He Y; He YJ; Gao J; Chen S; Du C; Wang T; Sun W; Huang Y; Wang C; Wang J
Peptides; 2021 Nov; 145():170638. PubMed ID: 34419496
[TBL] [Abstract][Full Text] [Related]
15.
Tiwari V
Biol Open; 2020 Oct; 9(10):. PubMed ID: 32878881
[TBL] [Abstract][Full Text] [Related]
16. Carnosine to Combat Novel Coronavirus (nCoV): Molecular Docking and Modeling to Cocrystallized Host Angiotensin-Converting Enzyme 2 (ACE2) and Viral Spike Protein.
Saadah LM; Deiab GIA; Al-Balas Q; Basheti IA
Molecules; 2020 Nov; 25(23):. PubMed ID: 33260592
[TBL] [Abstract][Full Text] [Related]
17. A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor.
Rajpoot S; Ohishi T; Kumar A; Pan Q; Banerjee S; Zhang KYJ; Baig MS
Drugs R D; 2021 Sep; 21(3):273-283. PubMed ID: 34324175
[TBL] [Abstract][Full Text] [Related]
18. Repositioning of histamine H
Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
[TBL] [Abstract][Full Text] [Related]
19. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.
Basit A; Ali T; Rehman SU
J Biomol Struct Dyn; 2021 Jul; 39(10):3605-3614. PubMed ID: 32396773
[TBL] [Abstract][Full Text] [Related]
20. Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro.
Lu J; Hou Y; Ge S; Wang X; Wang J; Hu T; Lv Y; He H; Wang C
Life Sci; 2021 Feb; 266():118889. PubMed ID: 33310043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
